3 July 2025 – Rotterdam, The Netherlands – Pan Cancer T is pleased to announce the appointment of Helen Tayton-Martin as independent director to its Supervisory Board.
Dr. Tayton-Martin was most recently Chief Business & Strategy Officer of Adaptimmune plc, a position held from October 2022 until March 2025. She previously served as Chief Business Officer from 2017 and Chief Operating Officer from 2008.
As a Co-founder and original COO of Adaptimmune, Dr. Tayton-Martin, oversaw the transition of operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations, and private and public financing through to its Nasdaq IPO. In August 2024, Adaptimmune received marketing approval for the first engineered TCR-T cell therapy, TECELRA®, to treat synovial sarcoma. Dr. Tayton-Martin was responsible for all Adaptimmune’s strategic partnerships, including those with Astellas, Genentech (a member of the Roche Group), GlaxoSmithKline and Galapagos NV.
Prior to her 17 years with Adaptimmune, Dr. Tayton-Martin spent 15 years working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence, business development, alliance management, and company operations (with Chiltern International, Sandoz, Pasteur Merieux and Technomark). She also previously served as a nonexecutive director of Trillium Therapeutics Inc. from October 2017 through the sale of the company in November 2021 to Pfizer Inc. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.
The inclusion of Helen Tayton-Martin expands Pan Cancer T’s Supervisory Board to five members as Helen joins John Tchelingerian (Chairman and independent director), Chris Bangma, Michel Briejer and Dharminder Chahal. Helen attended her first Supervisory Board meeting on 10 June 2025 in Rotterdam, the Netherlands.
John Tchelingerian, Chair of Pan Cancer T, said: “I am very pleased to welcome Helen to the Supervisory Board. She is a talented and highly respected leader who brings decades of scientific, R&D and corporate development leadership experience to Pan Cancer T, with a compelling industry track record developing TCR-T cell therapies at Adaptimmune.”
About Pan Cancer T
Pan Cancer T is an immunotherapy company based in Rotterdam, The Netherlands, developing next-generation TCR-T cell therapies for solid cancer. By focusing on unique cancer-specific targets, we aim to extend the reach of T cell therapies to new patient populations. Our proprietary next-generation gene engineering enhances T cell fitness, designed to prolong the duration of clinical responses. The Company has ongoing R&D programs to develop safe and effective adoptive T cell therapies amenable to large cohorts of patients with triple negative breast cancer (TNBC) as well as cancers of the bladder, ovary, colorectum, prostate, skin, oesophagus, lung, or brain.
Our lead product, PCT1:CO-STIM, features an IP-protected TCR against ROPN1, a novel target expressed in over 90% of TNBC and melanoma patients. It also incorporates our proprietary TCR:CO-STIM technology to overcome immune suppression in solid cancers. Preclinical data demonstrates strong safety and efficacy, positioning PCT1:CO-STIM for a first-in-human clinical trial in TNBC, offering new hope to patients with limited options.
For more information, please visit: www.pancancer-t.com
Pan Cancer T’s strong investment potential was highlighted at MEET2WIN with two awards, giving CEO Rachel Abbott a platform to present in depth and receive direct feedback from leading European oncology experts and top pharma companies.
Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have agreed to...
Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round.
On 5th June, our CEO, Rachel Abbott, was pleased to represent Pan Cancer T in the EIT Health Catapult finals at the health.tech global summit in Munich.
Amongst a record number of applicants, Pan Cancer T’s EIC Accelerator proposal has been awarded the Seal of Excellence.
Pan Cancer T has been selected as semi finalist of the EIT Health Catapult venture challenge
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Pan Cancer T is presenting preclinical data at CIMT and SITC 2023
“I am excited to join Pan Cancer T´s Scientific Advisory Board,” said Prof. Dr. Chiara Bonini. “T cell therapies hold tremendous promises for tumor patients and the development of TCR T therapies is just gaining momentum. I am convinced that Pan Cancer T will play a pioneering role in this field, as the Company is working on the main challenges in the field: identifying novel tumor antigens and leveraging engineering technology to enhance the T cells´ durability.”
Expanded investor syndicate strengthens the company’s financial position and investor base